(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Yunhong CTI Ltd., Rumble, and CASI Pharmaceuticals.

The three biggest losers today are China Jo-Jo Drugstores, Viking Therapeutics, and NextEra Energy.

Winners today

1. Yunhong CTI Ltd. (CTIB) – 21.83%

Yunhong CTI Ltd. develops, produces, distributes, and sells consumer products in the United States and internationally. It offers novelty products, including foil balloons; latex balloons under the Partyloons name; and toy balloon products, which include punch balls, water bombs, and Animal Twisties, as well as other inflatable toy items. The company also offers packaging films and custom film products for food, and other commercial and packaging applications; produces and distributes home organization and container products; assembles and sells Candy Blossom product line; and distribute party goods. It primarily serves various retail outlets, including general merchandise stores, discount and drugstore chains, grocery chains, card and gift shops, and party goods stores, as well as florists and balloon decorators. The company sells its products directly, as well as through a network of distributors and wholesalers, retail chains, and independent sales representatives. The company was formerly known as CTI Industries Corporation and changed its name to Yunhong CTI Ltd. in January 2020. Yunhong CTI Ltd. was founded in 1975 and is headquartered in Lake Barrington, Illinois.

NASDAQ ended the session with Yunhong CTI Ltd. rising 21.83% to $2.40 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Yunhong CTI Ltd. has a trailing twelve months EPS of $-0.09.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.02%.

More news about Yunhong CTI Ltd..

2. Rumble (RUM) – 9.33%

Rumble Inc. operates video sharing platforms in the United States, Canada, and internationally. The company operates rumble.com, a platform where users can subscribe to channels to stay in touch with creators, and access video on-demand (VOD) and live content streamed by creators. It also operates locals.com, a subscription platform for creators and subscribers to engage through VOD, podcasts, live chat, polls, and community discussions; and Rumble Advertising Center (RAC), an online advertising management exchange. The company was founded in 2013 and is headquartered in Longboat Key, Florida.

NASDAQ ended the session with Rumble jumping 9.33% to $5.22 on Wednesday while NASDAQ rose 0.22% to $13,092.85.

Earnings Per Share

As for profitability, Rumble has a trailing twelve months EPS of $-0.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.81%.

More news about Rumble.

3. CASI Pharmaceuticals (CASI) – 9.23%

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

NASDAQ ended the session with CASI Pharmaceuticals jumping 9.23% to $2.13 on Wednesday while NASDAQ rose 0.22% to $13,092.85.

Earnings Per Share

As for profitability, CASI Pharmaceuticals has a trailing twelve months EPS of $-2.92.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -56.14%.

Volatility

CASI Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.13%, a negative 0.60%, and a positive 2.98%.

CASI Pharmaceuticals’s highest amplitude of average volatility was 5.88% (last week), 2.94% (last month), and 2.98% (last quarter).

Yearly Top and Bottom Value

CASI Pharmaceuticals’s stock is valued at $2.13 at 17:32 EST, way below its 52-week high of $3.70 and way higher than its 52-week low of $1.45.

More news about CASI Pharmaceuticals.

4. Cyclacel Pharmaceuticals (CYCCP) – 8.06%

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

NASDAQ ended the session with Cyclacel Pharmaceuticals rising 8.06% to $16.75 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Cyclacel Pharmaceuticals has a trailing twelve months EPS of $-2.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -134.49%.

More news about Cyclacel Pharmaceuticals.

5. Upland Software (UPLD) – 5.88%

Upland Software, Inc. provides cloud-based enterprise work management software in the United States, the United Kingdom, Canada, and internationally. It offers a family of software applications under the Upland brand in the areas of marketing, sales, contact center, project management, information technology, business operations, and human resources and legal. The company also provides professional services, such as implementation, data extraction, integration and configuration, and training services, as well as customer support services. It serves large global corporations, various government agencies, and small and medium-sized businesses, as well as financial, consulting, technology, manufacturing, media, telecommunication, political, healthcare, life sciences, and retail and hospitality sectors. The company was formerly known as Silverback Enterprise Group, Inc. and changed its name to Upland Software, Inc. in November 2013. Upland Software, Inc. was incorporated in 2010 and is headquartered in Austin, Texas.

NASDAQ ended the session with Upland Software rising 5.88% to $4.42 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Upland Software has a trailing twelve months EPS of $-6.09.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -62.01%.

Yearly Top and Bottom Value

Upland Software’s stock is valued at $4.42 at 17:32 EST, way below its 52-week high of $11.88 and way higher than its 52-week low of $2.47.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 58% and a negative 43.2%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth declined by 7.1%, now sitting on 309.91M for the twelve trailing months.

More news about Upland Software.

6. Kosmos Energy (KOS) – 5.84%

Kosmos Energy Ltd. engages in the exploration and production of oil and gas properties along the Atlantic Margins in the United States. The company's primary assets include production projects located in offshore Ghana, Equatorial Guinea, and the U.S. Gulf of Mexico, as well as a gas projects located in offshore Mauritania and Senegal. It also undertakes a proven basin exploration program in Equatorial Guinea and the U.S. Gulf of Mexico. Kosmos Energy Ltd. was founded in 2003 and is headquartered in Dallas, Texas.

NYSE ended the session with Kosmos Energy jumping 5.84% to $8.15 on Wednesday, after three successive sessions in a row of gains. NYSE rose 0.09% to $15,394.69, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Kosmos Energy has a trailing twelve months EPS of $0.46.

PE Ratio

Kosmos Energy has a trailing twelve months price to earnings ratio of 17.72. Meaning, the purchaser of the share is investing $17.72 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.41%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 26.3% and a negative 8.7%, respectively.

Moving Average

Kosmos Energy’s value is way above its 50-day moving average of $7.12 and way higher than its 200-day moving average of $6.85.

More news about Kosmos Energy.

7. FibroGen (FGEN) – 5.47%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen rising 5.47% to $0.92 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ rose 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.76.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1015.79%.

Yearly Top and Bottom Value

FibroGen’s stock is valued at $0.92 at 17:32 EST, way under its 52-week high of $25.69 and way above its 52-week low of $0.70.

More news about FibroGen.

8. Generac Holdlings (GNRC) – 5.33%

Generac Holdings Inc. designs, manufactures, and sells power generation equipment, energy storage systems, energy management devices and solutions, and other power products for the residential, light commercial, and industrial markets worldwide. The company offers residential automatic standby generators, automatic transfer switch, air-cooled engine residential standby generators, and liquid-cooled engine generators; residential storage solution consists of a system of batteries, an inverter, photovoltaic optimizers, power electronic controls, and other components; Mobile Link, a remote monitoring system for home standby generators; smart home solutions, such as smart thermostats and a suite of home monitoring products; smart water heater controllers; residential clean energy solutions; and portable and inverter generators; outdoor power equipment, including trimmers, field and brush mowers, log splitters, stump grinders, chipper shredders, lawn and leaf vacuums, and pressure washers and water pumps; and battery-powered turf care products. It also provides commercial and industrial products comprising cleaner-burning natural gas fueled generators; light-commercial standby generators and related transfer switches; stationary generators and related transfer switches; single-engine industrial generators; industrial standby generators; industrial transfer switches; light towers, mobile generators, and mobile energy storage systems; and aftermarket service parts and product accessories. The company distributes its products through independent residential dealers, industrial distributors and dealers, national and regional retailers, e-commerce partners, electrical, HVAC and solar wholesalers, catalogs, equipment rental companies and distributors, and solar installers; and directly to end users. The company was founded in 1959 and is headquartered in Waukesha, Wisconsin.

NYSE ended the session with Generac Holdlings rising 5.33% to $108.72 on Wednesday while NYSE jumped 0.09% to $15,394.69.

Earnings Per Share

As for profitability, Generac Holdlings has a trailing twelve months EPS of $2.31.

PE Ratio

Generac Holdlings has a trailing twelve months price to earnings ratio of 47.07. Meaning, the purchaser of the share is investing $47.07 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.87%.

Yearly Top and Bottom Value

Generac Holdlings’s stock is valued at $108.72 at 17:32 EST, way under its 52-week high of $244.14 and way above its 52-week low of $86.29.

Volatility

Generac Holdlings’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.87%, a negative 0.34%, and a positive 2.29%.

Generac Holdlings’s highest amplitude of average volatility was 1.28% (last week), 1.11% (last month), and 2.29% (last quarter).

More news about Generac Holdlings.

9. Cloudflare (NET) – 5.18%

CloudFlare, Inc. operates as a cloud services provider that delivers a range of services to businesses worldwide. The company provides an integrated cloud-based security solution to secure a range of combination of platforms, including public cloud, private cloud, on-premise, software-as-a-service applications, and IoT devices; and website and application security products comprising web application firewall, bot management, distributed denial of service, API gateways, SSL/TLS encryption, secure origin connection, and rate limiting products. It also offers website and application performance solutions, including content delivery, load balancing, DNS, agro smart routing, video stream delivery, content optimization, virtual backbone, always online, and cloudflare waiting room and registrar; and network services, which deliver network connectivity, security, and performance to customers as a service, including WAN, WARP, magic transit, magic firewall, cloudflare network interconnect, and spectrum. In addition, the company provides zero trust services, such as cloudflare access, cloudflare gateway, remote browser isolation, cloud access security broker, cloudflare area 1 email security, and data loss prevention products that protect, inspect, and privilege data. Further, it provides developer-based solutions consisting of cloudflare workers, pages, stream, and images, as well as Cloudflare Data Localization suite, a tool that set rules and controls at the network edge; durable objects and R2 object storage products; Consumer DNS Resolver, a consumer app to browse the Internet; and consumer VPN for consumers to secure and accelerate traffic on mobile devices. The company serves customers in the technology, healthcare, financial services, consumer and retail, and non-profit industries, as well as government. CloudFlare, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

NYSE ended the session with Cloudflare jumping 5.18% to $59.62 on Wednesday while NYSE jumped 0.09% to $15,394.69.

Earnings Per Share

As for profitability, Cloudflare has a trailing twelve months EPS of $-0.68.

Sales Growth

Cloudflare’s sales growth is 31.9% for the ongoing quarter and 29.7% for the next.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 66.7% and 66.7%, respectively.

More news about Cloudflare.

10. TherapeuticsMD (TXMD) – 5.14%

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD rising 5.14% to $3.07 on Wednesday, following the last session’s upward trend. NASDAQ rose 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $3.23.

PE Ratio

TherapeuticsMD has a trailing twelve months price to earnings ratio of 0.95. Meaning, the purchaser of the share is investing $0.95 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1134.2%.

More news about TherapeuticsMD.

Losers Today

1. China Jo-Jo Drugstores (CJJD) – -8.56%

China Jo-Jo Drugstores, Inc., together with its subsidiaries, operates as a retailer and distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours. In addition, it operates online drugstore that retails OTC drugs and nutritional supplements, as well as sells products through third-party platforms. Further, the company distributes third-party pharmaceutical products primarily to trading companies, as well as cultivates and wholesales herbs used for TCM. As of March 31, 2021, it had 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores. The company was founded in 2003 and is headquartered in Hangzhou, the People's Republic of China.

NASDAQ ended the session with China Jo-Jo Drugstores falling 8.56% to $0.23 on Wednesday, after five successive sessions in a row of losses. NASDAQ jumped 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, China Jo-Jo Drugstores has a trailing twelve months EPS of $-1.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -107.29%.

More news about China Jo-Jo Drugstores.

2. Viking Therapeutics (VKTX) – -8.11%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics sliding 8.11% to $10.96 on Wednesday, following the last session’s upward trend. NASDAQ rose 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.88%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 4.8% and positive 7.7% for the next.

Volume

Today’s last reported volume for Viking Therapeutics is 1584870 which is 14.57% below its average volume of 1855320.

Volatility

Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.05%, a negative 0.80%, and a positive 2.63%.

Viking Therapeutics’s highest amplitude of average volatility was 5.05% (last week), 2.90% (last month), and 2.63% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be overbought (>=80).

More news about Viking Therapeutics.

3. NextEra Energy (NEE) – -7.64%

NextEra Energy, Inc., through its subsidiaries, generates, transmits, distributes, and sells electric power to retail and wholesale customers in North America. The company generates electricity through wind, solar, nuclear, coal, and natural gas facilities. It also develops, constructs, and operates long-term contracted assets that consists of clean energy solutions, such as renewable generation facilities, battery storage projects, and electric transmission facilities; sells energy commodities; and owns, develops, constructs, manages and operates electric generation facilities in wholesale energy markets. As of December 31, 2022, the company had approximately 32,100 megawatts of net generating capacity; approximately 88,000 circuit miles of transmission and distribution lines; and 871 substations. It serves approximately 12 million people through approximately 5.8 million customer accounts in the east and lower west coasts of Florida. The company was formerly known as FPL Group, Inc. and changed its name to NextEra Energy, Inc. in 2010. NextEra Energy, Inc. was founded in 1925 and is headquartered in Juno Beach, Florida.

NYSE ended the session with NextEra Energy sliding 7.64% to $60.35 on Wednesday, after four sequential sessions in a row of losses. NYSE jumped 0.09% to $15,394.69, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, NextEra Energy has a trailing twelve months EPS of $4.05.

PE Ratio

NextEra Energy has a trailing twelve months price to earnings ratio of 14.9. Meaning, the purchaser of the share is investing $14.9 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.5%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 1.2% and 11.8%, respectively.

Volume

Today’s last reported volume for NextEra Energy is 13969900 which is 68.88% above its average volume of 8272020.

More news about NextEra Energy.

4. Canopy Growth (CGC) – -7.11%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth falling 7.11% to $0.86 on Wednesday, after two successive sessions in a row of losses. NASDAQ rose 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-1.74.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 60% and 82.5%, respectively.

More news about Canopy Growth.

5. Charles & Colvard Ltd. (CTHR) – -6.79%

Charles & Colvard, Ltd. operates as a fine jewelry company in the United States and internationally. The company manufactures, markets, and distributes moissanite jewels and finished moissanite jewelry under the Charles & Colvard Created Moissanite brand; and premium moissanite gemstones under the Forever One brand name. It also markets and distributes lab grown diamonds, and finished jewelry with lab grown diamonds under the Caydia brand. The company sells its products at wholesale prices to distributors, manufacturers, retailers, and designers; and to end-consumers at retail prices through charlesandcolvard.com, third-party online marketplaces, drop-ship, and other e-commerce outlets. Charles & Colvard, Ltd. was founded in 1995 and is headquartered in Morrisville, North Carolina.

NASDAQ ended the session with Charles & Colvard Ltd. dropping 6.79% to $0.69 on Wednesday, after two successive sessions in a row of losses. NASDAQ rose 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Charles & Colvard Ltd. has a trailing twelve months EPS of $-0.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.99%.

Yearly Top and Bottom Value

Charles & Colvard Ltd.’s stock is valued at $0.69 at 17:32 EST, way under its 52-week high of $1.26 and above its 52-week low of $0.68.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Charles & Colvard Ltd.’s EBITDA is -9.86.

Revenue Growth

Year-on-year quarterly revenue growth declined by 31.9%, now sitting on 33.69M for the twelve trailing months.

Sales Growth

Charles & Colvard Ltd.’s sales growth is negative 13.9% for the present quarter and negative 10.8% for the next.

More news about Charles & Colvard Ltd..

6. Dawson Geophysical Company (DWSN) – -5.71%

Dawson Geophysical Company provides onshore seismic data acquisition and processing services in the United States and Canada. The company acquires and processes 2-D, 3-D, and multi-component seismic data for its clients, including oil and gas companies, and independent oil and gas operators, as well as providers of multi-client data libraries. Its seismic crews supply seismic data primarily to companies engaged in the exploration and development of oil and natural gas on land and in land-to-water transition areas. The company also serves the potash mining industry. Dawson Geophysical Company was founded in 1952 and is headquartered in Midland, Texas. Dawson Geophysical Company is a subsidiary of Wilks Brothers, LLC.

NASDAQ ended the session with Dawson Geophysical Company falling 5.71% to $2.31 on Wednesday while NASDAQ jumped 0.22% to $13,092.85.

Earnings Per Share

As for profitability, Dawson Geophysical Company has a trailing twelve months EPS of $-0.67.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.28%.

Sales Growth

Dawson Geophysical Company’s sales growth for the next quarter is 21.3%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 324.3%, now sitting on 60.41M for the twelve trailing months.

Volume

Today’s last reported volume for Dawson Geophysical Company is 60940 which is 828.11% above its average volume of 6566.

Moving Average

Dawson Geophysical Company’s value is way higher than its 50-day moving average of $1.98 and way higher than its 200-day moving average of $1.84.

More news about Dawson Geophysical Company.

7. Capitol Federal Financial (CFFN) – -5.69%

Capitol Federal Financial, Inc. operates as the holding company for Capitol Federal Savings Bank that provides various retail banking products and services in the United States. The company accepts a range of deposit products, including savings accounts, money market deposit accounts, interest-bearing and non-interest-bearing checking accounts, and certificates of deposit. It also provides various loan products, such as one- to four-family residential real estate loans, commercial real estate and commercial construction, and commercial and industrial loans, as well as consumer loans, which include home equity, lines of credit, home improvement, and vehicle loans, as well as loans secured by saving deposits. In addition, the company offers mobile, telephone, and online banking services, as well as bill payment services; operates a call center; and invests in various securities. As of September 30, 2022, it operated a network of 54 branches, including 45 traditional branches and nine in-store branches located in nine counties throughout Kansas and three counties in Missouri. The company serves the metropolitan areas of Topeka, Wichita, Lawrence, Manhattan, Emporia, and Salina, Kansas, and a portion of the metropolitan area of greater Kansas City. Capitol Federal Financial, Inc. was founded in 1893 and is headquartered in Topeka, Kansas.

NASDAQ ended the session with Capitol Federal Financial dropping 5.69% to $4.64 on Wednesday while NASDAQ jumped 0.22% to $13,092.85.

Earnings Per Share

As for profitability, Capitol Federal Financial has a trailing twelve months EPS of $0.43.

PE Ratio

Capitol Federal Financial has a trailing twelve months price to earnings ratio of 10.79. Meaning, the purchaser of the share is investing $10.79 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.31%.

Yearly Top and Bottom Value

Capitol Federal Financial’s stock is valued at $4.64 at 17:32 EST, way under its 52-week high of $8.93 and above its 52-week low of $4.63.

Volume

Today’s last reported volume for Capitol Federal Financial is 912046 which is 9.67% above its average volume of 831598.

More news about Capitol Federal Financial.

8. Newmont Mining (NEM) – -5.39%

Newmont Corporation engages in the production and exploration of gold. It also explores for copper, silver, zinc, and lead. The company has operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. As of December 31, 2022, it had proven and probable gold reserves of 96.1 million ounces and land position of 61,500 square kilometers. The company was founded in 1916 and is headquartered in Denver, Colorado.

NYSE ended the session with Newmont Mining falling 5.39% to $37.28 on Wednesday while NYSE jumped 0.09% to $15,394.69.

Earnings Per Share

As for profitability, Newmont Mining has a trailing twelve months EPS of $-0.95.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.61%.

Moving Average

Newmont Mining’s value is below its 50-day moving average of $40.59 and way under its 200-day moving average of $45.22.

Yearly Top and Bottom Value

Newmont Mining’s stock is valued at $37.28 at 17:32 EST, under its 52-week low of $37.45.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.3%, now sitting on 11.2B for the twelve trailing months.

More news about Newmont Mining.

9. Aspen Group (ASPU) – -5.24%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group falling 5.24% to $0.16 on Wednesday while NASDAQ rose 0.22% to $13,092.85.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Aspen Group’s stock is considered to be oversold (<=20).

More news about Aspen Group.

10. China Natural Resources (CHNR) – -5.13%

China Natural Resources, Inc., through its subsidiaries, engages in the exploration and mining of metal properties in the People's Republic of China. It explores for lead, silver, and other nonferrous metals. The company holds interest in the Moruogu Tong mine that covers an area of 7.81 square kilometers located in Bayannaoer City, Inner Mongolia. It also offers equipment for rural wastewater treatment; and engineering, procurement, and construction services related to wastewater treatment. The company was incorporated in 1993 and is headquartered in Sheung Wan, Hong Kong. China Natural Resources, Inc. is a subsidiary of Feishang Group Limited.

NASDAQ ended the session with China Natural Resources dropping 5.13% to $1.85 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.22% to $13,092.85, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, China Natural Resources has a trailing twelve months EPS of $-2.08.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.4%.

Volume

Today’s last reported volume for China Natural Resources is 1477 which is 98.07% below its average volume of 76679.

More news about China Natural Resources.

Stay up to date with our winners and losers daily report